Pharmacological assistance for psychotherapy
Emerging Trends in Drugs Addictions and Health January 1, 2021 Jessica Lochtenberg, Ari P. Kirshenbaum, Matthew W. Johnson 2 citations
This narrative review examines the potential of short-acting pharmacotherapies—d-cycloserine, propranolol, and psychedelics—delivered alongside psychotherapy for anxiety, mood, and substance-dependence disorders. It outlines the basic science supporting their use, particularly neurobiological learning and memory theories. Although efficacy remains under investigation, the authors suggest these medically-assisted psychotherapies may offer advantages over traditional treatments, including fewer chronic side effects, lower toxicity and abuse potential. Some clinical research indicates that adjunctive pharmacotherapies may strengthen the psychotherapeutic alliance and yield better long-term outcomes. If proven clinically efficacious and safe, these approaches could expand treatment options for mental health patients.